Framework Journal · one stock, one dated entry

Recorded 2025-12-31 · Permanent

Zhengye Biotechnology Holding Ltd ZYBT

Clears the common standard

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China.

The label
Markup

read at $0.70

Zhengye Biotechnology Holding Ltd holds its Markup at $0.70.

PHINPOOPSC
  • PHPhase · the trend structure carries the Markup label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · passes the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2025-12-31
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 31 days
Price$0.70
ValuationN/A trailing · N/A forward price to earnings
Values screenPASS · score 70.0
BetaN/A

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Revenue growth-40.9%
revenue is shrinking
Profit margin-60.0%
currently unprofitable
Return on equity-25.2%
not currently earning a positive return on equity
Debt to equity0.24
minimal debt — a conservative balance sheet
Current ratio1.14
adequate liquidity, worth monitoring
Market cap$33M
Employees269

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to China and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in ZYBT's space worth a look

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 24%. Entered 2026-07-18 · Markdown

The dated journal · newest first, never edited

2026-07-18 Markdown $0.83 +0.0% Entry 3

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 86%. Our forward projection puts the odds of a 10% gain over the next month near 24%.

2026-07-03 Markdown $0.83 +0.0% Entry 2

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Markdown $0.83 Entry 1

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $1.00 -9.7% · $903 -9.7%
2 months $1.06 -15.1% · $849 -15.1%
3 months $0.77 +16.6% · $1,166 +16.6%
6 months $2.03 -55.7% · $444 -55.7%
1 year $6.25 -85.6% · $144 -85.6%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever ZYBT does next, these words stay.

Zhengye Biotechnology Holding Ltd · ZYBT · Markup · $0.70
Recorded 2025-12-31 · before the outcome · scored mechanically

Get our weekly market brief free.